Aurobindo Pharma

Sept 15 (Reuters) - Aurobindo Pharma Limited ARBN.NS:

• RECEIVES USFDA FINAL APPROVAL FOR BECLOMETHASONE DIPROPIONATE HFA INHALATION AEROSOL

Further company coverage: ARBN.NS

(([email protected];;))

Sept 11 (Reuters) - Aurobindo Pharma Limited ARBN.NS:

• COMPLETION OF US FDA INSPECTION AT UNIT-IV OF APITORIA PHARMA PRIVATE

• INSPECTION CONCLUDED WITH ZERO OBSERVATIONS

Further company coverage: ARBN.NS

(([email protected];))

Aug 31 (Reuters) - Aurobindo Pharma Limited ARBN.NS:

• AUROBINDO PHARMA - UNIT LANNETT COMPANY LAUNCHES GENERIC ADVAIR DISKUS IN US

Source text: ID:nBSE3tB8F4

Further company coverage: ARBN.NS

(([email protected];;))

BENGALURU, Aug 27 (Reuters) - Diary of India economic, corporate events on August 27

ECONOMIC, CORPORATE .BSE500 EVENTS

(Compiled by Bengaluru Newsroom)

(([email protected]))

Aug 24 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA- US FDA CONDUCTED INSPECTION AT LANNETT COMPANY LLC FROM 17TH TO 21ST AUGUST 2026

• AUROBINDO PHARMA- INSPECTION CONCLUDED WITH FOUR OBSERVATIONS, WHICH ARE PROCEDURAL IN NATURE

Source text: [ID:]

Further company coverage: ARBN.NS

(([email protected];))

Aug 21 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - US FDA CONDUCTED INSPECTION AT AUROPEPTIDES FROM AUGUST 17 TO AUGUST 21

• AUROBINDO PHARMA - INSPECTION CONCLUDES WITH ONE OBSERVATION ON FACILITY AND EQUIPMENT MAINTENANCE

• AUROBINDO PHARMA - CORRECTIVE ACTION WAS ALREADY INITIATED DURING THE COURSE OF THE INSPECTION

Source text: [ID:]

Further company coverage: ARBN.NS

(([email protected];))

Aug 17 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - CLASSIFICATION OF US FDA INSPECTION AT UNIT'S RALEIGH PLANT AS VOLUNTARY ACTION INDICATED

• AUROBINDO PHARMA - AT END OF INSPECTION, FORM 483 WAS ISSUED WITH TOTAL OF 11 OBSERVATIONS

Further company coverage: ARBN.NS

(([email protected];))

Aurobindo Pharma said Unit I of its wholly owned Eugia Pharma Specialities subsidiary received a warning letter from the US Food and Drug Administration. The letter followed an Official Action Indicated status disclosed on May 24, and the unit contributed about 2% of group revenue. The company said existing supplies to US markets were unaffected. Eugia Pharma Specialities operated the group’s sterile-injectables business. Aurobindo reported FY26 revenue of ₹33,653 crore and an EBITDA margin of 20.4%.

Powered by Tijori

Aug 5 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA Q1 CONSOL NET PAT 10.33 BILLION RUPEES

• AUROBINDO PHARMA Q1 CONSOL TOTAL REVENUE FROM OPERATIONS 91.5 BILLION RUPEES

• AUROBINDO PHARMA - TO FILE SCHEME OF AMALGAMATION OF EUGIA STERILES AND EUGIA SEZ WITH EUGIA PHARMA SPECIALITIES

Source text: [ID:]

Further company coverage: ARBN.NS

(([email protected];;))

June 22 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - AUROBINDO PHARMA USA RECEIVES FTC APPROVAL TO ACQUIRE LANNETT COMPANY

• AUROBINDO PHARMA - DEAL VALUED AT $250 MILLION

Source text: ID:nnAZN4T3F3C

Further company coverage: ARBN.NS

(([email protected];))

Aurobindo Pharma has received approval from the US Federal Trade Commission for its acquisition of Lannett Company, a deal first announced in July 2025. The company said it expects the transaction to close before the end of June, a faster timeline than previously indicated. The approval removes a key regulatory hurdle for the purchase, which is being executed through Aurobindo's US subsidiary. The acquisition had been anticipated to close in early Q2 of the current fiscal year but now appears set to complete sooner. Aurobindo did not disclose the financial terms of the deal again in the filing. The Lannett business is expected to strengthen Aurobindo's presence in the US generics market.

Powered by Tijori

June 19 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - UNIT TO BUY 100% OF LANNETT COMPANY

• AUROBINDO PHARMA - OBTAINS US FTC APPROVAL FOR LANNETT ACQUISITION

• AUROBINDO PHARMA - EXPECTS LANNETT DEAL TO CLOSE BEFORE END OF JUNE 2026

Source text: ID:nBSE51F0Jx

Further company coverage: ARBN.NS

(([email protected];))

Adds FTC quote and context to paragraphs 2 and 3

June 18 (Reuters) - The U.S. Federal Trade Commission is requiring Aurobindo Pharma Limited ARBN.NS to divest four different generic drug products to complete its $250 million acquisition of Lannett Company Inc., the agency said on Thursday in a statement.

The agency will require Aurobindo to divest to Quagen Pharmaceuticals an immunosuppressant prescribed to prevent organ transplant rejection, a cholesterol management drug, a drug prescribed to treat dry mouth in radiation therapy patients and a drug prescribed to reduce stomach acid.

"Aurobindo’s acquisition of Lannett would combine two of a limited number of competitors in the markets for four different generic pharmaceutical products that provide critical relief for patients, ranging from drugs used to prevent organ transplant rejection to tablets that treat dry mouth after radiation therapy," the FTC said.

(Reporting by Ryan Patrick Jones, Writing by Christian Martinez; Editing by Doina Chiacu)

(([email protected]))

** Shares of India's Aurobindo Pharma ARBN.NS down 1.3% to 1,453.8 rupees, snapping a three-session winning streak

** Stock set for biggest percentage fall since May 27, if losses hold

** US FDA on Friday flagged inspection classification of subsidiary's facility in Telangana as "official action indicated" - most serious FDA inspection classification

** Regulator concluded the inspection with 11 observations, co said

** ARBN noted it is committed to maintaining quality manufacturing standards across all facilities

** YTD, stock up 12.47%

(Reporting by Saikeerthi in Bengaluru)

(([email protected]; (+91) 8296756080))

Aurobindo Pharma's wholly owned subsidiary Eugia Pharma Specialities Ltd received an official action indicated classification from the US FDA for its Unit-III formulation manufacturing facility in Pashamylaram, Telangana. The inspection took place from January 27 to February 6, 2026, and concluded with 11 observations. The OAI designation signals that the agency found serious violations and may pursue enforcement actions such as a warning letter or import restrictions. Aurobindo said the classification would have no immediate financial or operational impact and vowed to maintain high manufacturing standards. The development follows a similar OAI classification for the company's Unit-I facility earlier this year.

Powered by Tijori

June 12 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - FDA CLASSIFIES EUGIA UNIT-III INSPECTION AS OFFICIAL ACTION INDICATED (OAI)

• AUROBINDO PHARMA - US FDA INSPECTED EUGIA UNIT-III FROM JAN 27 TO FEB 6, 2026 WITH 11 OBSERVATIONS

Source text: ID:nNSE4MQDjD

Further company coverage: ARBN.NS

(([email protected];))

June 4 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - RECEIVES FINAL US FDA APPROVAL FOR TOFACITINIB TABLETS, 5 MG AND 10 MG

Source text: ID:nNSE3hZSH6

Further company coverage: ARBN.NS

(([email protected];))

** Aurobindo Pharma ARBN.NS shares fall 3.8% to 1,488.3 rupees

** Co's Q4 revenue from operations up 5.6% and net profit up 2%, while EBITDA slips 0.5% and EBITDA margin falls by 104 basis points

** The co's accounting quality is improving, but concerns remain due to project delays, weak free cash flow, and high expenses that are not clearly classified, Ambit Capital said ahead of results

** Stock may remain discounted as promoter pledges rise and shareholder payouts increase alongside growing capital and debt in group private infra, real estate ventures, brokerage says

** ARBN trades at forward 12-months PE of 20.08 vs industry median of 26.51

** Twenty-one of 26 brokerages rate the stock "buy" or higher; median PT is 1,425 rupees

** YTD, ARBN up 25.4% vs 9.1% rise in Nifty Pharma Index .NIPHARM

(Reporting by Abhinav Parmar in Bengaluru)

(([email protected];))

May 21 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• MARCH-QUARTER CONSOL NET PAT 9.21 BILLION RUPEES

• MARCH-QUARTER CONSOL TOTAL REVENUE FROM OPERATIONS 88.53 BILLION RUPEES

Source text: [ID:]

Further company coverage: ARBN.NS

(([email protected];))

May 6 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - US FDA INSPECTS AUROBINDO PHARMA UNIT-VII IN TELANGANA FROM JAN 28 TO FEB 10, 2026

• AUROBINDO PHARMA - US FDA ISSUES FORM 483 WITH 9 OBSERVATIONS FOR AUROBINDO PHARMA UNIT-VII

• AUROBINDO PHARMA - UNIT RECEIVES EIR CLASSIFIED AS "VOLUNTARY ACTION INDICATED", FDA HAS CONCLUDED THAT THIS INSPECTION IS NOW CLOSED

Source text: ID:nBSE15L6dt

Further company coverage: ARBN.NS

(([email protected];))

May 1 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - UNIT SECURES HEALTH CANADA NOC FOR BEVQOLVA™ BEVACIZUMAB BIOSIMILAR

Further company coverage: ARBN.NS

(([email protected];))

April 17 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• RECEIVES USFDA APPROVAL FOR GLYCEROL PHENYLBUTYRATE ORAL LIQUID, 1.1 GRAMS PER ML

• TO LAUNCH GLYCEROL PHENYLBUTYRATE ORAL LIQUID IMMEDIATELY

Source text: ID:nBSE8FZb3T

Further company coverage: ARBN.NS

(([email protected];))

April 15 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - THERANYM BIOLOGICS ANNOUNCES ADDITIONAL PRODUCT SCHEDULE WITH MSD

• AUROBINDO PHARMA - THERANYM TO BUILD DRUG SUBSTANCE FACILITY WITH 60 KL BIOREACTOR CAPACITY

• AUROBINDO PHARMA - THERANYM TO INVEST USD 150-175 MILLION IN MANUFACTURING FACILITY

Source text: ID:nBSEb22ZnT

Further company coverage: ARBN.NS

(([email protected];))

April 7 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - RECEIVES USFDA APPROVAL FOR DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS

Source text: ID:nNSE1YtdYk

Further company coverage: ARBN.NS

(([email protected];))

April 6 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• CURATEQ BIOLOGICS ANNOUNCES POSITIVE PHASE 3 RESULTS FOR OMALIZUMAB BIOSIMILAR BP11

• PHASE 3 STUDY MET ALL PRIMARY ENDPOINTS IN CSU PATIENTS AT 300 MG DOSE

Source text: ID:nNSE2RrdG0

Further company coverage: ARBN.NS

(([email protected];))

March 31 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - TO CONSIDER BUYBACK OF EQUITY SHARES

Source text: ID:nBSE9sWkfw

Further company coverage: ARBN.NS

(([email protected];))

March 20 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• AUROBINDO PHARMA - US FDA INSPECTS UNIT-V API FACILITY OF APITORIA PHARMA, AUROBINDO SUBSIDIARY

• AUROBINDO PHARMA - UNIT-V RECEIVES EIR CLASSIFYING FACILITY AS VAI; INSPECTION CLOSED

Source text: ID:nBSE9t0t0d

Further company coverage: ARBN.NS

(([email protected];;))

March 17 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• US FDA ISSUES FORM 483 WITH 9 OBSERVATIONS TO EUGIA PHARMA UNIT-II

• US FDA CLASSIFIES EUGIA PHARMA UNIT-II AS 'OFFICIAL ACTION INDICATED'

Source text: ID:nNSE46tRKP

Further company coverage: ARBN.NS

(([email protected];;))

March 13 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:

• GETS TAX DEMAND AND PENALTY OF 776.1 MILLION RUPEES EACH

Source text: ID:nBSEbyqSK8

Further company coverage: ARBN.NS

(([email protected];))